- Home
- PANW vs GILD Comparison
PANW vs GILD Comparison
Compare PANW & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PANW
- GILD
- Stock Information
- Founded
- PANW 2005
- GILD 1987
- Country
- PANW United States
- GILD United States
- Employees
- PANW N/A
- GILD N/A
- Industry
- PANW Computer peripheral equipment
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PANW Technology
- GILD Health Care
- Exchange
- PANW Nasdaq
- GILD Nasdaq
- Market Cap
- PANW 132.3B
- GILD 113.0B
- IPO Year
- PANW 2012
- GILD 1992
- Fundamental
- Price
- PANW $186.78
- GILD $92.57
- Analyst Decision
- PANW Buy
- GILD Buy
- Analyst Count
- PANW 43
- GILD 26
- Target Price
- PANW $201.40
- GILD $96.71
- AVG Volume (30 Days)
- PANW 5.8M
- GILD 7.6M
- Earning Date
- PANW 02-18-2025
- GILD 02-11-2025
- Dividend Yield
- PANW N/A
- GILD 3.33%
- EPS Growth
- PANW 332.61
- GILD N/A
- EPS
- PANW 3.85
- GILD 0.10
- Revenue
- PANW $8,288,200,000.00
- GILD $28,299,000,000.00
- Revenue This Year
- PANW $16.28
- GILD $6.50
- Revenue Next Year
- PANW $15.44
- GILD $0.36
- P/E Ratio
- PANW $48.56
- GILD $915.61
- Revenue Growth
- PANW 15.00
- GILD 3.31
- 52 Week Low
- PANW $130.05
- GILD $62.07
- 52 Week High
- PANW $207.24
- GILD $98.90
- Technical
- Relative Strength Index (RSI)
- PANW 41.44
- GILD 54.42
- Support Level
- PANW $186.54
- GILD $90.27
- Resistance Level
- PANW $207.24
- GILD $93.59
- Average True Range (ATR)
- PANW 6.58
- GILD 2.19
- MACD
- PANW -1.69
- GILD -0.17
- Stochastic Oscillator
- PANW 7.96
- GILD 62.18
About PANW Palo Alto Networks Inc.
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three fourths of the Global 2000.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).